Welcome to our dedicated page for Entera Bio Ltd. SEC filings (Ticker: ENTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Entera Bio Ltd. filings document a Nasdaq-listed Israeli clinical-stage biopharmaceutical company developing oral peptide and protein replacement therapies. Its recent Form 8-K disclosures cover financial results, Regulation FD updates, EB613 regulatory and clinical-development communications, and business updates across oral peptide programs.
The filing record also documents material agreements and capital structure matters, including collaboration and license arrangements with OPKO, a private placement involving ordinary shares, pre-funded warrants and ordinary share warrants, and governance disclosures related to board appointments. These filings frame ENTX's operating updates, securities structure, partnership obligations and public-company governance.
Entera Bio Ltd. director Sean Ellis reported an open-market purchase of 10,000 ordinary shares of Entera Bio on March 5, 2026. The weighted average purchase price was $1.23 per share, with individual trades executed between $1.2287 and $1.245. Following this transaction, Ellis directly owns 188,098 ordinary shares of Entera Bio.
Entera Bio Ltd. filed a current report describing a key clinical milestone for its lead osteoporosis candidate EB613. The company has submitted to the FDA a streamlined Phase 3 protocol, statistical analysis plan, and open-label extension synopsis under its existing IND for oral teriparatide.
The planned registrational Phase 3 study will enroll 750 postmenopausal women with osteoporosis and use percentage change in total hip bone mineral density at 12 months, rather than 24 months, as the primary endpoint. Entera plans to advance a new single-tablet, once-daily formulation of EB613 directly into this trial and anticipates initiating the study in late 2026, with topline results expected in the second half of 2028.
Entera Bio Ltd. director Steven D. Rubin reported an open-market purchase of 5,000 ordinary shares at $1.49 per share on February 12, 2026. Following this transaction, he directly beneficially owns 15,000 ordinary shares of Entera Bio.
Entera Bio Ltd. director Haya Taitel reported buying 7,500 ordinary shares on February 10, 2026. The Form 4 shows a purchase at a weighted average price of $1.48 per share, executed through multiple trades between $1.47 and $1.4799, with the holding reported as direct ownership.
Entera Bio Ltd. director transaction: Director Germano J. Geno reported buying 20,000 ordinary shares of Entera Bio Ltd. on February 10, 2026. The shares, each with a par value of NIS 0.0000769, were purchased in a direct ownership transaction at a price of $1.49 per share.
Entera Bio director Steven D. Rubin reported a share purchase. On February 9, 2026, he bought 10,000 Ordinary Shares of Entera Bio Ltd. at $1.20 per share.
Following this transaction, Rubin beneficially owns 10,000 Ordinary Shares, all held in direct ownership.
Entera Bio Ltd. director Ellis Sean reported buying 18,000 ordinary shares on February 9, 2026. The purchase was coded as an open-market or private purchase at a weighted average price of $1.24 per share, bringing his directly held stake to 178,098 ordinary shares.
The shares were acquired in multiple trades, with prices ranging from $1.18 to $1.299 per share. Sean is listed as a director of Entera Bio, and the filing shows the ownership as held directly rather than through an intermediary entity.
Entera Bio Ltd. director Germano Geno J filed an initial Form 3 reporting no securities beneficially owned in the company. The filing identifies him as a director, with the event date listed as 02/04/2026 and the statement signed by an attorney-in-fact.
Entera Bio Ltd. has appointed pharmaceutical industry veteran Geno J. Germano as Chairman of the Board and a Class III director, effective February 4, 2026. He will serve until the 2026 annual shareholder meeting or until a successor is chosen.
Germano brings more than three decades of leadership experience, including senior roles at Pfizer where he led a roughly $14 billion innovative medicines portfolio, and board positions at multiple biotech companies. He will receive standard non-employee director cash and equity compensation under Entera’s 2018 Equity Incentive Plan.
Gerald Lieberman resigned as Chairman and as a director effective February 4, 2026, with the company stating his resignation did not result from any disagreement over operations, policies, or practices. Entera highlighted this leadership change as it plans 2026 clinical milestones, including a Phase 3 study of EB613 for osteoporosis and a first-in-human study of Long-Acting Oral PTH for hypoparathyroidism.
Entera Bio Ltd. director Steven D. Rubin filed an initial ownership report on Form 3 related to the company. The filing identifies him as a director and states in the explanation section that "No securities are beneficially owned," indicating he reports no current beneficial ownership of Entera Bio securities.